Show simple item record

dc.contributor.authorLee, Daniel Y
dc.contributor.authorLim, Kwang Suk
dc.contributor.authorValencia, Gabriel M
dc.contributor.authorJung, Minjin
dc.contributor.authorBull, David A
dc.contributor.authorWon, Young-Wook
dc.date.accessioned2019-05-23T21:06:50Z
dc.date.available2019-05-23T21:06:50Z
dc.date.issued2018-11-01
dc.identifier.citationLee, D. Y., Lim, K. S., Valencia, G. M., Jung, M., Bull, D. A., Won, Y.‐W., Adv. Sci. 2018, 5, 1800447. https://doi.org/10.1002/advs.201800447en_US
dc.identifier.issn2198-3844
dc.identifier.pmid30479915
dc.identifier.doi10.1002/advs.201800447
dc.identifier.urihttp://hdl.handle.net/10150/632391
dc.description.abstractConventional combinatorial anticancer therapy has shown promising outcomes; still, a significant interest in developing new methods to reinforce and possibly merge chemotherapy and immunotherapy persists. Here, a new one-step method that immediately modifies immune cells into a targeted form of chemoimmunotherapy through spontaneous and rapid incorporation of hydrophobized antibody-drug conjugates (ADCs) on the surface of immune cells is presented. Therapeutic objectives of this approach include targeted delivery of a potent chemotherapeutic agent to avoid adverse effects, enhancing the mobilization of infused immune cells toward tumor sites, and preserving the intense cytotoxic activities of immune cells against tumor cells. The embedding of hydrophobized ADCs on the immune cell membrane using the strategy in this study provides noninvasive, nontoxic, and homogenous modifications that transiently arm immune cells with highly potent cytotoxic drugs targeted toward cancer cells. The resulting surface-engineered immune cells with ADCs significantly suppress the tumor growth and drive the eradication of target cancer cells through combinatorial anticancer effects. This novel strategy allows convenient and timely preparation of advanced chemoimmunotherapy on a single immune cell to treat various types of cancer.en_US
dc.description.sponsorshipNational Heart, Lung, and Blood Institute of the National Institutes of Health [R01HL138242]en_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/full/10.1002/advs.201800447en_US
dc.rights© 2018 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the Creative Commons Attribution License.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectantibody–drug conjugatesen_US
dc.subjectcanceren_US
dc.subjectchemoimmunotherapyen_US
dc.subjectimmune cellsen_US
dc.subjectone‐step methoden_US
dc.titleOne-Step Method for Instant Generation of Advanced Allogeneic NK Cellsen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Med, Dept Surg, Div Cardiothorac Surgen_US
dc.identifier.journalADVANCED SCIENCEen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)
refterms.dateFOA2019-05-23T21:06:51Z


Files in this item

Thumbnail
Name:
Lee_et_al-2018-Advanced_Science.pdf
Size:
4.620Mb
Format:
PDF
Description:
Final Published version

This item appears in the following Collection(s)

Show simple item record

© 2018 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the Creative Commons Attribution License.
Except where otherwise noted, this item's license is described as © 2018 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the Creative Commons Attribution License.